<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Neonatal thrombosis: Management and outcome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Neonatal thrombosis: Management and outcome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Neonatal thrombosis: Management and outcome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anthony KC Chan, MBBS, FRCPC, FRCPath
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mihir D Bhatt, MD, FRCPC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sarah O'Brien, MD, MSc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph A Garcia-Prats, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Armsby, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 02, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thrombotic events are uncommon in newborns; however, they are increasingly recognized as complications of contemporary neonatal care and they contribute to neonatal morbidity and mortality.
        </p>
        <p>
         The management of neonatal thrombosis is reviewed here. The clinical features and diagnosis of neonatal thrombosis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5912.html" rel="external">
          "Neonatal thrombosis: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
         This topic focuses on thrombotic events occurring outside of the central nervous system. Thrombosis involving the central nervous system (ie, neonatal stroke) is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5912.html" rel="external">
          "Neonatal thrombosis: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6157.html" rel="external">
          "Stroke in the newborn: Classification, manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114253.html" rel="external">
          "Stroke in the newborn: Management and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          GENERAL APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Newborns are at risk for thrombosis because of the unique characteristics of their coagulation and fibrinolytic system as compared with older age groups, as well as because of triggers such as indwelling catheters. Because these risk factors usually are transient, the recurrence risk is low. Therefore, the primary goal of treatment in this age group is to prevent or minimize end-organ damage [
         <a href="#rid1">
          1,2
         </a>
         ]. Rarely, a neonate has a chronic condition that predisposes to thrombosis, such as neonatal purpura fulminans or congenital nephrotic syndrome; in such cases, longer-term treatment is warranted. (See
         <a class="local">
          'Special circumstances'
         </a>
         below.)
        </p>
        <p>
         Data on different management strategies and the efficacy and safety of specific therapeutic agents in the neonatal population are limited. The approach to an individual infant must balance the risks and benefits.
        </p>
        <p>
         In most cases of neonatal thrombosis, consultation with a pediatric hematologist is advised. If such expertise is not available at the institution caring for the neonate, a free service is provided by a group of clinicians with extensive experience in neonatal thrombosis (call 1-800-NOCLOTS) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          TREATMENT BASED ON THROMBUS LOCATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         When choosing between conservative management (ie, supportive care and close monitoring) versus initiating anticoagulation, the approach depends upon the location of the thrombus and whether there are associated symptoms.
        </p>
        <p class="headingAnchor" id="H4212119687">
         <span class="h2">
          Catheter-associated thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For neonates with catheter-associated venous thrombosis (excluding renal vein thrombosis [RVT], portal vein thrombosis [PVT], and right atrial [RA] thrombosis, which are discussed below), our suggested approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For neonates with
         <strong>
          asymptomatic
         </strong>
         catheter-associated thrombosis, we suggest supportive care and close monitoring of the size of the thrombus [
         <a href="#rid1">
          1,4
         </a>
         ]. If the thrombus is associated with a central venous catheter (CVC) or umbilical venous catheter (UVC), the catheter should be removed if possible. Follow-up imaging is obtained initially within three to five days and if stable, it is repeated one to two weeks later. If the thrombus is stable or decreasing, subsequent ultrasound monitoring can be spaced out to every one to two months until resolved.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The rationale for this approach is that most asymptomatic thrombi resolve without treatment (particularly if the catheter is removed) and conservative management avoids bleeding complications that can be associated with anticoagulation therapy. However, initial treatment with an anticoagulant is a reasonable option when it is not feasible to remove the catheter, due to the patient's clinical condition.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If serial monitoring demonstrates extension of the thrombus or if the patient becomes symptomatic from the thrombus, we suggest anticoagulation as described in the next section [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For
         <strong>
          symptomatic
         </strong>
         catheter-associated thrombosis, we suggest therapeutic anticoagulation (typically with low molecular weight heparin LMWH). (See
         <a class="local">
          'Choice of agent'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The optimal duration of therapy is uncertain. Our approach is to monitor the thrombus with serial ultrasounds. If the thrombus resolves and the patient is asymptomatic by six weeks, we discontinue anticoagulation. Otherwise, we continue anticoagulation for three months or until the thrombus has resolved and the patient is asymptomatic, whichever is shorter. Clinical trial data suggest that six weeks of anticoagulant therapy is sufficient for most patients with CVC-associated venous thrombosis [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CVCs and UVCs associated with thrombosis should be removed, if possible, immediately or after three to five days of anticoagulation [
         <a href="#rid1">
          1
         </a>
         ]. When the decision is made to remove the CVC or UVC, we typically remove it after three to five days of initial anticoagulation; however, there are scant data to support this approach and it is reasonable to remove the CVC or UVC sooner. If the CVC or UVC remains in place at the time of completion of therapeutic anticoagulation, we suggest treatment with a prophylactic dose of LMWH until the device is removed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of
         <strong>
          arterial
         </strong>
         catheter-associated thrombosis is discussed below. (See
         <a class="local">
          'Arterial thrombosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Renal vein thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal management approach for neonates with RVT is uncertain, and practice varies. The available data are limited to small retrospective case series [
         <a href="#rid6">
          6,7
         </a>
         ]. The need for and choice of anticoagulant is based on whether the infant has unilateral or bilateral involvement, whether there is associated renal insufficiency, and whether the thrombus extends into the inferior vena cava (IVC) [
         <a href="#rid1">
          1
         </a>
         ]. For all neonates with RVT, if there is a CVC or UVC in place in the IVC, it should be removed if possible.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unilateral RVT with normal renal function AND without extension into the IVC
         </strong>
         – In our practice, neonates with unilateral RVT with normal renal function and without extension into the IVC are treated with anticoagulation unless the patient has a high bleeding risk. The rationale for treating such infants is to minimize potential complications of RVT (eg, chronic kidney disease and hypertension) [
         <a href="#rid8">
          8,9
         </a>
         ]. However, since the risk of these complications is relatively low in patients with unilateral RVT (as compared with bilateral RVT), an alternative approach is to manage initially with supportive care and close monitoring. If the thrombosis progresses or there is extension into the IVC, anticoagulation should be started.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When the decision is made to treat with anticoagulant therapy, the typical treatment duration is three months. A shorter duration is reasonable if the thrombus resolves on follow-up imaging and the patient is asymptomatic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bilateral RVT, associated renal insufficiency, OR extension into the IVC
         </strong>
         – For neonates with bilateral RVT, compromised renal function, or extension into the IVC, we suggest therapeutic anticoagulation for three months unless there are contraindications to its use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The choice of agent and dosing for anticoagulant therapy depend on the neonate's renal function, as discussed below. (See
         <a class="local">
          'Choice of agent'
         </a>
         below and
         <a class="local">
          'Dose'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with extensive thrombus that compromises renal function, concomitant use of thrombolytic therapy can be considered to potentially reduce the risk of developing chronic renal failure [
         <a href="#rid1">
          1,7
         </a>
         ]. (See
         <a class="local">
          'Thrombolytic therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         In a systematic review of 13 case series published from 1992 to 2006 involving 271 neonates with RVT (70 percent unilateral, 30 percent bilateral), therapeutic anticoagulation was used in 60 percent of cases and 40 percent were managed conservatively [
         <a href="#rid6">
          6
         </a>
         ]. Thrombolytic therapy was used in a small minority of patients (approximately 10 percent). In the seven studies (143 infants) that reported long-term outcomes, 74 percent of patients had evidence of kidney atrophy on imaging at last follow-up, with similar rates in heparin-treated and -untreated patients.
        </p>
        <p class="headingAnchor" id="H1407583335">
         <span class="h2">
          Portal vein thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         PVT is almost always associated with the use of a UVC, and, thus, the UVC should be removed if possible. The benefit of anticoagulation in neonatal PVT is uncertain since many resolve without intervention [
         <a href="#rid10">
          10
         </a>
         ]. Thus, for most neonates with PVT that is limited to the left portal vein, we suggest conservative management with supportive care and serial monitoring. If the thrombus extends into the main portal vein and/or IVC, anticoagulation should be initiated (typically with LMWH) [
         <a href="#rid10">
          10
         </a>
         ]. The usual treatment duration is three months, though a shorter duration is reasonable if the thrombus resolves on follow-up imaging and the patient is asymptomatic.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Right atrial thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         RA thrombi are usually associated with CVCs. They can compromise cardiac function or lead to pulmonary embolism. If possible, the catheter should be removed. We usually treat RA thrombosis with anticoagulation (typically with LMWH) unless there is a contraindication to its use. The usual treatment duration is three months, though a shorter duration is reasonable if the thrombus resolves on follow-up imaging and the patient is asymptomatic. If cardiac function is compromised, we begin thrombolytic therapy. (See
         <a class="local">
          'Thrombolytic therapy'
         </a>
         below.)
        </p>
        <p>
         A systematic review that included data from neonates and children (mean age 3.6 years) with RA thrombus suggested that thrombi with low-risk features (ie, small size [&lt;2 cm] and not pedunculated, mobile, or snake-shaped) can be treated conservatively without anticoagulation [
         <a href="#rid11">
          11
         </a>
         ]. However, it should be noted that the critical clot size depends on the age of the child [
         <a href="#rid12">
          12
         </a>
         ]. In neonates, smaller thrombi may be considered high risk. If conservative management is chosen, the thrombus should be monitored closely and anticoagulation should be started if the thrombus increases in size [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Arterial thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment should be initiated for arterial thrombosis that causes significant impairment of blood flow to an extremity or vital organ. If the thrombus is associated with an arterial catheter, it should be removed. We usually begin anticoagulation therapy with LMWH or
         <a class="drug drug_pediatric" data-topicid="13349" href="/z/d/drug information/13349.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) [
         <a href="#rid1">
          1
         </a>
         ]. If the thrombus is thought to be limb-threatening, a surgical consultation should be obtained for a multidisciplinary approach to management.
        </p>
        <p>
         Thrombolytic therapy may be warranted in cases of arterial thrombosis that are life-threatening or that jeopardize the viability of a limb or if a vital organ is jeopardized [
         <a href="#rid1">
          1
         </a>
         ]. Concomitant anticoagulant therapy (typically using UFH without a bolus) is typically provided during thrombolytic therapy. The thrombus should be monitored by clinical examination and ultrasonography (see
         <a class="local">
          'Thrombolytic therapy'
         </a>
         below). Surgical thrombectomy is an appropriate alternative in cases in which thrombolysis is contraindicated.
        </p>
        <p class="headingAnchor" id="H2008782631">
         <span class="h2">
          Central nervous system
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of neonatal stroke is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/114253.html" rel="external">
          "Stroke in the newborn: Management and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1745216876">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Before starting therapeutic anticoagulation, the following tests should be obtained:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory tests
         </strong>
         , including:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Activated partial thromboplastin time (aPTT)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prothrombin time (PT) and international normalized ratio (INR)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Plasma fibrinogen concentration
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complete blood count, including platelet count
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Kidney function tests (blood urea nitrogen and creatinine)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Liver transaminases (if treatment with a direct oral anticoagulant [DOAC] is planned, which is uncommon)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cranial ultrasound
         </strong>
         – This is especially important for preterm infants, who are at increased risk of developing an intracranial hemorrhage (see
         <a class="medical medical_review" href="/z/d/html/5051.html" rel="external">
          "Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Patients with significant thrombocytopenia or evidence of coagulopathy prior to treatment (eg, prolonged PT or aPTT, low fibrinogen level) should undergo evaluation for the cause. Anticoagulant therapy may need to be deferred until the abnormality is treated or resolved. Prior to starting anticoagulant treatment, the platelet count should be &gt;50,000/microL and the fibrinogen concentration should be &gt;100 mg/dL (&gt;1 g/L). (See
         <a class="medical medical_review" href="/z/d/html/4979.html" rel="external">
          "Neonatal thrombocytopenia: Etiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/97752.html" rel="external">
          "Neonatal thrombocytopenia: Clinical manifestations, evaluation, and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H664750991">
         <span class="h1">
          ANTICOAGULANT AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H2938233942">
         <span class="h2">
          Choice of agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most neonates requiring treatment for thrombosis, we suggest low molecular weight heparin (LMWH) rather than other agents.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preference for LMWH
         </strong>
         – LMWHs have many advantages over
         <a class="drug drug_pediatric" data-topicid="13349" href="/z/d/drug information/13349.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) [
         <a href="#rid13">
          13,14
         </a>
         ]. These include greater bioavailability when given by subcutaneous injection, longer duration of anticoagulant effect, and clearance that is independent of dose (which results in a more predictable response). LMWHs do not require intravenous access and require less laboratory monitoring and dose adjustment compared with UFH; these are important for newborns with poor venous access. (See
         <a class="local">
          'Low molecular weight heparin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limited role for UFH
         </strong>
         – UFH may be preferred for initial therapy in some circumstances, such as in patients with kidney failure or those with bleeding risks who require finely tuned titration and the ability to quickly turn on or off the infusion (eg, patients requiring multiple surgeries or other invasive procedures, patients receiving concomitant thrombolytic therapy). (See
         <a class="local">
          'Unfractionated heparin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral agents
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Direct oral anticoagulants (DOACs) –
         </strong>
         DOACs include oral factor Xa inhibitors (
         <a class="drug drug_pediatric" data-topicid="127822" href="/z/d/drug information/127822.html" rel="external">
          rivaroxaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         ) and the direct thrombin inhibitor
         <a class="drug drug_pediatric" data-topicid="132189" href="/z/d/drug information/132189.html" rel="external">
          dabigatran
         </a>
         ). These agents do
         <strong>
          not
         </strong>
         play a role in the treatment of thrombosis in preterm neonates since data on their safety and efficacy in this population are extremely limited. While rivaroxaban is approved for use in term neonates (≥37 weeks gestation), it is generally not a first-line agent for young infants. None of the other DOAC agents are approved for use in infants &lt;3 months of age. (See
         <a class="local">
          'Direct oral anticoagulants'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vitamin K antagonist (
         </strong>
         <strong>
          warfarin
         </strong>
         <strong>
          )
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          Warfarin
         </a>
         generally should
         <strong>
          not
         </strong>
         be used in neonates because it has an unacceptably high risk of bleeding. (See
         <a class="local">
          'Warfarin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3071135038">
         <span class="h2">
          Low molecular weight heparin
         </span>
        </p>
        <p class="headingAnchor" id="H2152785372">
         <span class="h3">
          Dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         Commercially available LMWH agents differ from one another both chemically and pharmacokinetically; dosing is
         <strong>
          not
         </strong>
         interchangeable between agents [
         <a href="#rid15">
          15
         </a>
         ]. LMWH agents that are approved by the US Food and Drug Administration for different clinical indications include
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="110082" href="/z/d/drug information/110082.html" rel="external">
          dalteparin
         </a>
         , ardeparin, and
         <a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">
          tinzaparin
         </a>
         . Additional agents approved by other regulatory agencies include
         <a class="drug drug_general" data-topicid="10060" href="/z/d/drug information/10060.html" rel="external">
          nadroparin
         </a>
         and reviparin. We suggest not using dalteparin or tinzaparin in neonates, because data on their use are very limited. Pediatric dosing guidance for enoxaparin and other LMWH agents is provided in the table  (
         <a class="graphic graphic_table graphicRef64075" href="/z/d/graphic/64075.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         In the United States, the agent used most commonly for treatment of neonatal thrombosis is
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         , for which dosing is as follows [
         <a href="#rid16">
          16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapeutic anticoagulation
         </strong>
         – For treatment of thrombosis in term neonates, we initiate
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         at a dose of 1.5 to 1.7 mg/kg per dose given subcutaneously twice daily; the initial dose for preterm neonates is 2 mg/kg per dose given subcutaneously twice daily [
         <a href="#rid16">
          16-19
         </a>
         ]. For ease of administration, we typically round the dose to whole milligrams [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The dose of
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         required to achieve therapeutic anti-Xa levels is higher in neonates compared with older children. In particular, preterm neonates generally require higher doses and take longer to reach therapeutic levels compared with other populations [
         <a href="#rid19">
          19,22
         </a>
         ]. In a systematic review of 19 studies (1112 pediatric patients), the mean therapeutic enoxaparin dose (using twice-daily dosing) was 2.1 mg/kg per dose for preterm neonates and 1.7 mg/kg per dose for term neonates, as compared with 1.2 mg/kg per dose in children aged one to six years old [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prophylaxis
         </strong>
         – For prophylaxis,
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         is initiated at 0.75 mg/kg per dose given subcutaneously twice daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with mild to moderate renal insufficiency
         </strong>
         – The dose of
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         (or other LMWH agent) should be adjusted in patients with renal insufficiency. There are no available data to guide practice in this setting. The authors' approach is to decrease the dose in proportion to the degree of renal insufficiency (eg, for infants estimated to have a 50 percent reduction in renal function, the daily enoxaparin dose is reduced by 50 percent, either by reducing each dose or changing the frequency to once per day). Subsequent dosing adjustments should be made according to the anti-factor Xa level. To ensure that the drug does not accumulate, both the peak and trough levels of anti-factor Xa should be monitored. (See
         <a class="local">
          'Monitoring and dose adjustment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with severe renal failure
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          Enoxaparin
         </a>
         and other LMWHs should not be used in patients with severe renal failure. Patients with severe renal failure who require ongoing anticoagulation should be managed with UFH. (See
         <a class="local">
          'Unfractionated heparin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H442970718">
         <span class="h3">
          Monitoring and dose adjustment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The LMWH dose is adjusted according to the anti-factor Xa level measured four to six hours after the dose [
         <a href="#rid1">
          1,17,23
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients receiving therapeutic anticoagulation with LMWH, the target range for anti-factor Xa levels is 0.5 to 1 units/mL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients receiving LMWH for prophylaxis, the target range for anti-factor Xa levels is 0.1 to 0.3 units/mL
        </p>
        <p>
        </p>
        <p>
         It should be noted that the reference ranges for anti-factor Xa levels in monitoring LMWH were established in older age groups. The therapeutic range for neonates has not been well established [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         A nomogram for LMWH dose titration in pediatric patients is available on Lexicomp's
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         drug information topic. (See
         <a class="drug drug_pediatric" href="/z/d/drug information/13270.html" rel="external">
          "Enoxaparin (including biosimilars available in Canada): Pediatric drug information"
         </a>
         .)
        </p>
        <p>
         In addition to monitoring anti-Xa levels, the complete blood count including platelet count should be monitored periodically. The frequency depends upon comorbidities and bleeding risk (ranging from daily in critically ill patients to once every other week or monthly in a stable outpatient). The platelet count should be maintained at &gt;50,000/microL during treatment.
        </p>
        <p class="headingAnchor" id="H393931332">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on limited information, LMWH appears to be safe and effective in newborns. A prospective cohort study including 173 children (one-third of whom were &lt;3 months old) described the experience using
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         both for treatment of documented thrombosis and for prevention in patients at high risk for thromboembolism [
         <a href="#rid17">
          17
         </a>
         ]. Of patients who received therapeutic enoxaparin, 94 percent demonstrated resolution of the thrombus. In patients receiving prophylaxis, 96 percent had no symptoms of new or recurrent thromboembolic events. In a pooled analysis of six studies including a total of 138 neonates treated with LMWH, 97.1 percent had treatment success without experiencing recurrent thrombosis [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Data supporting the efficacy of LMWH in older infants and children are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Low molecular weight heparin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3982474222">
         <span class="h3">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main adverse effect of LMWH is bleeding [
         <a href="#rid19">
          19,25
         </a>
         ]. In a systematic review of 30 pediatric studies including 1329 patients, many of whom were &lt;3 months old, rates of major bleeding associated with LMWH were 1.8 percent for patients receiving therapeutic dosing and 0.6 percent for patients receiving prophylactic dosing [
         <a href="#rid19">
          19
         </a>
         ]. Minor bleeding complications occurred in 16 and 1 percent, respectively. In a separate pooled analysis of 21 studies that were limited to neonates &lt;28 days old treated with LMWH (n = 458), 3.9 percent experienced clinically apparent bleeding [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Other potential adverse effects include heparin-induced thrombocytopenia (HIT) and osteoporosis. However, these are rare and the risk appears to be lower with LMWH compared with UFH, as discussed below. (See
         <a class="local">
          'Adverse effects'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3337638543">
         <span class="h3">
          Reversal
         </span>
         <span class="headingEndMark">
          —
         </span>
         If serious bleeding occurs, LMWH should be discontinued and
         <a class="drug drug_pediatric" data-topicid="12746" href="/z/d/drug information/12746.html" rel="external">
          protamine sulfate
         </a>
         administered to reverse the heparin effect. However, it should be noted that protamine only partially reverses the effects of LMWH [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         The dose of
         <a class="drug drug_pediatric" data-topicid="12746" href="/z/d/drug information/12746.html" rel="external">
          protamine sulfate
         </a>
         depends upon the dose of
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         and the time since the dose was administered:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         was given
         <strong>
          within eight hours
         </strong>
         , the maximum dose of protamine is 1 mg per 1 mg enoxaparin, given by slow intravenous (IV) push
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If
         <strong>
          &gt;8 hours have passed
         </strong>
         since the last
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         dose, the dose of protamine is 0.5 mg per 1 mg enoxaparin, given by slow IV push
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H880522701">
         <span class="h2">
          Unfractionated heparin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The advantages of UFH are its rapid reversibility and low cost. Disadvantages include its unpredictable pharmacokinetic response and resultant requirement for frequent monitoring.
        </p>
        <p>
         Infusion of UFH in newborns requires a dedicated IV catheter. This avoids interruption of anticoagulation therapy by infusion of other medications and minimizes the risk of inadvertent flushing of the catheter that may lead to excessive anticoagulation.
        </p>
        <p class="headingAnchor" id="H1744674154">
         <span class="h3">
          Dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dosing of UFH in neonates is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loading dose – In our practice, we usually do
         <strong>
          not
         </strong>
         administer a loading dose to neonates unless the thrombus is severe. When a loading dose is used, it is given as 75 to 100 units/kg IV. The loading dose should be withheld or reduced if there are significant bleeding risks (eg, extremely low birth weight, septicemia, disseminated intravascular coagulation). We omit the loading dose in most cases; based on our experience, it is not necessary and limited data suggest that the activated partial thromboplastin time (aPTT) can be markedly elevated after the bolus [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintenance dose – The initial maintenance dose is 28 units/kg per hour IV.
        </p>
        <p>
        </p>
        <p>
         The above dosing is supported by a prospective study of UFH treatment in 65 children with thrombosis, of whom 29 were &lt;1 year old, including 13 newborns [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1879515539">
         <span class="h3">
          Monitoring and titration
         </span>
         <span class="headingEndMark">
          —
         </span>
         UFH dosing in the neonate should be titrated using
         <strong>
          both
         </strong>
         the anti-factor Xa level and aPTT  (
         <a class="graphic graphic_algorithm graphicRef134270" href="/z/d/graphic/134270.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The target anti-factor Xa level is 0.35 to 0.7 units/mL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The target aPTT range is 1.5 to 2 times the upper limit of normal
        </p>
        <p>
        </p>
        <p>
         Monitoring both of these is necessary for neonates because they have an increased clearance rate of UFH compared with older children or adults [
         <a href="#rid28">
          28
         </a>
         ]. aPTT values can be used alone to facilitate dose adjustments but only after establishing the aPTT range that corresponds to the target anti-factor Xa activity range in an individual patient.
        </p>
        <p>
         In addition to monitoring anti-Xa levels and aPTT, the complete blood count with platelet count should be monitored daily. The platelet count should be maintained at &gt;50,000/microL during UFH treatment.
        </p>
        <p>
         The efficacy of UFH may be reduced in newborns relative to older children because the physiologic plasma concentration of antithrombin (AT) is low in early infancy [
         <a href="#rid29">
          29,30
         </a>
         ]. Thus, in infants requiring high doses of UFH and/or with difficulty achieving target anti-factor Xa activity, it may be reasonable to check the patient's AT level and administer AT concentrate if AT levels are low (based on age-appropriate reference ranges). Data to support this practice are limited [
         <a href="#rid2">
          2,31
         </a>
         ]. However, AT administration is generally avoided in preterm infants due to concerns of potential antiangiogenic effects and evidence of increased morbidity and mortality associated with its use in this population [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p>
         It should be noted that the reference ranges for aPTT and anti-factor Xa levels in monitoring UFH were established in older age groups. The therapeutic range for neonates has not been well established [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Other factors to consider when adjusting the UFH dose include the clinical significance of the thrombus and the potential risk of bleeding [
         <a href="#rid1">
          1,34
         </a>
         ].
        </p>
        <p>
         The challenges of UFH therapy in young infants were demonstrated in a series of 100 infants &lt;6 months old who were treated with UFH according to the titration protocol outlined above [
         <a href="#rid35">
          35
         </a>
         ]. Approximately two-thirds of infants had successful treatment (ie, decreased or stable thrombus size) and achieved therapeutic anti-factor Xa levels on a median UFH dose of 33 units/kg per hour. However, 17 percent of patients never achieved therapeutic anti-factor Xa levels despite prolonged UFH therapy at relatively high doses. Moreover, 11 percent of patients had a major bleeding episode.
        </p>
        <p class="headingAnchor" id="H1873184590">
         <span class="h3">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal duration of therapy is uncertain. The usual duration is six weeks to three months. Serial ultrasound monitoring can be used to guide decision-making. Therapy is generally continued until the thrombus has resolved or for a maximum duration of three months [
         <a href="#rid1">
          1
         </a>
         ]. In our practice, we generally switch to LMWH if treatment is needed for longer than two weeks.
        </p>
        <p class="headingAnchor" id="H1144624118">
         <span class="h3">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major side effects of heparin are bleeding, HIT, and osteoporosis [
         <a href="#rid13">
          13
         </a>
         ]. These can occur with either UFH or LMWH, though the risk is greater with UFH.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bleeding
         </strong>
         – The risk of bleeding in newborns is uncertain, but it likely relates to the dose of heparin and underlying disorders that predispose to bleeding. Few studies have evaluated the risk of UFH-related bleeding in the neonatal population. In a study of 100 neonates and infants &lt;6 months old who were treated with UFH, 11 percent experienced a serious bleeding event [
         <a href="#rid35">
          35
         </a>
         ]. In other studies, the incidence of bleeding ranged from 1 to 33 percent [
         <a href="#rid24">
          24,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIT
         </strong>
         – HIT is a rare complication of heparin therapy in neonates. Most of the reported cases have occurred in neonates undergoing cardiac surgery or requiring extracorporeal membrane oxygenation [
         <a href="#rid36">
          36-38
         </a>
         ]. However, the precise incidence of HIT in neonates is unknown because critically ill neonates commonly have thrombocytopenia and/or thrombosis due to other mechanisms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HIT should be considered in a newborn with acute onset of severe thrombocytopenia (ie, &gt;50 percent fall in platelet count) that is temporally associated with exposure to heparin (either UFH or LMWH) and for which no other cause is apparent. Most neonates who develop thrombocytopenia while receiving heparin have other causes identified, and, thus, many can be continued on heparin therapy while maintaining the platelet count with transfusion, if necessary. If there is strong clinical suspicion for HIT, heparin should be discontinued and, if the patient requires ongoing anticoagulation, a non-heparinoid agent should be used (eg,
         <a class="drug drug_pediatric" data-topicid="13081" href="/z/d/drug information/13081.html" rel="external">
          argatroban
         </a>
         ). (See
         <a class="local">
          'Other agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HIT is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">
          "Clinical presentation and diagnosis of heparin-induced thrombocytopenia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">
          "Management of heparin-induced thrombocytopenia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Osteoporosis
         </strong>
         – While osteoporosis has been reported in adult patients receiving UFH for prolonged duration, there are few reports of this occurring in children and there is no information on this complication in newborns [
         <a href="#rid34">
          34,39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2036.html" rel="external">
          "Drugs that affect bone metabolism", section on 'Heparin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3535514930">
         <span class="h3">
          Reversal
         </span>
         <span class="headingEndMark">
          —
         </span>
         If bleeding occurs, the UFH infusion should be discontinued. For mild bleeding, stopping the infusion is generally sufficient. If the bleeding is more severe, the effects of heparin can be reversed using
         <a class="drug drug_pediatric" data-topicid="12746" href="/z/d/drug information/12746.html" rel="external">
          protamine sulfate
         </a>
         . Since heparin disappears rapidly from the circulation, only heparin given in the preceding two to four hours should be considered when calculating the protamine dose. Assuming the half-life of heparin to be one hour, one approach is to calculate the protamine dose as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Give 1 mg of protamine per 100 units of heparin received in the past hour (ie, the full neutralizing dose),
         <strong>
          plus
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Give 0.5 mg of protamine per 100 units of heparin received in the hour preceding that (ie, one-half the neutralizing dose)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3913178298">
         <span class="h2">
          Direct oral anticoagulants
         </span>
         <span class="headingEndMark">
          —
         </span>
         DOACs include the direct thrombin inhibitor
         <a class="drug drug_pediatric" data-topicid="132189" href="/z/d/drug information/132189.html" rel="external">
          dabigatran
         </a>
         and factor Xa inhibitors
         <a class="drug drug_pediatric" data-topicid="127822" href="/z/d/drug information/127822.html" rel="external">
          rivaroxaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         , and
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         . Rivaroxaban and dabigatran are the agents that are best studied in pediatric patients, but there are very few data on either agent in neonates. Rivaroxaban is approved by the US Food and Drug Administration for treatment of venous thromboembolism (VTE) in pediatric patients, including term neonates (≥37 weeks gestation) [
         <a href="#rid40">
          40,41
         </a>
         ]. Dabigatran is approved for treatment of VTE in pediatric patients ≥3 months old [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preterm neonates
         </strong>
         – DOACs do
         <strong>
          not
         </strong>
         play a role in the management of VTE in preterm neonates since data on their safety and efficacy in this population are extremely limited. None of the available DOAC agents are approved for use in preterm neonates.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Term neonates
         </strong>
         – DOACs play a very limited role in management of VTE in term neonates. Treatment with a DOAC is a reasonable alternative option for patients with VTE who are stable after receiving initial treatment with LMWH when there is a need to transition to an oral agent. However, for most neonates with VTE, we suggest treating with LMWH for the entire treatment course. LMWH is preferred over DOACs in most instances because there is greater experience with LMWH and its efficacy and safety are well established in this age group. By contrast, the efficacy and safety of DOACs remain uncertain in this population since young infants were underrepresented in the pediatric DOAC trials. However, cautious use of a DOAC is a reasonable alternative to LMWH in select circumstances (eg, if the infant requires long-term anticoagulation).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When treatment with a DOAC is selected, we suggest
         <a class="drug drug_pediatric" data-topicid="127822" href="/z/d/drug information/127822.html" rel="external">
          rivaroxaban
         </a>
         since it is the only agent approved for use in infants &lt;3 months old. The neonate should be transitioned to rivaroxaban only if they meet
         <strong>
          all
         </strong>
         of the following criteria [
         <a href="#rid43">
          43
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gestational age ≥37 weeks
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Weight ≥2.6 kg
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinically stable
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No hepatic disease or severe kidney impairment
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tolerating oral/enteral feeding for at least 10 days
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Received ≥5 days of parenteral anticoagulant therapy (typically with LMWH) before transitioning
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pediatric dosing of
         <a class="drug drug_pediatric" data-topicid="127822" href="/z/d/drug information/127822.html" rel="external">
          rivaroxaban
         </a>
         is summarized in the table  (
         <a class="graphic graphic_table graphicRef134264" href="/z/d/graphic/134264.html" rel="external">
          table 2
         </a>
         ). Additional details, including guidance on pretreatment testing, monitoring, management of DOAC-associated bleeding, and a discussion of the supporting evidence, are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Direct oral anticoagulants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2223477857">
         <span class="h2">
          Warfarin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          Warfarin
         </a>
         should
         <strong>
          not
         </strong>
         be used in newborns, because of the unacceptably high risk of bleeding [
         <a href="#rid39">
          39
         </a>
         ]. Warfarin's anticoagulant effect is mediated by reduction of the functional plasma concentration of the vitamin K-dependent coagulation factors (factors II, VII, IX, and X). However, the concentration of these factors is already physiologically low in newborns (often at a level similar to that seen in adults receiving warfarin therapy).
        </p>
        <p>
         In addition, newborns may have borderline low levels of vitamin K, increasing the risk of warfarin-induced bleeding. Because human milk has low concentrations of vitamin K, breastfed newborns are especially sensitive to the effect of
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          warfarin
         </a>
         . On the other hand, infant formulas are supplemented with vitamin K, rendering formula-fed newborns relatively resistant to treatment.
        </p>
        <p>
         Another problem with
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          warfarin
         </a>
         administration in newborns is its availability only in tablet form. Splitting or crushing the tablet into powder form may cause variability in the dose. In addition, treatment with warfarin requires frequent monitoring of the international normalized ratio (INR).
        </p>
        <p class="headingAnchor" id="H2788221561">
         <span class="h2">
          Other agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other anticoagulants include
         <a class="drug drug_pediatric" data-topicid="122584" href="/z/d/drug information/122584.html" rel="external">
          fondaparinux
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13081" href="/z/d/drug information/13081.html" rel="external">
          argatroban
         </a>
         , and
         <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">
          bivalirudin
         </a>
         . Use of these agents in neonates is generally limited to patients with HIT who require cessation of heparin and ongoing anticoagulation with non-heparin agents (argatroban and fondaparinux are the agents most commonly used in this setting) [
         <a href="#rid38">
          38,44
         </a>
         ]. These agents are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Parenteral direct thrombin inhibitors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1319.html" rel="external">
          "Fondaparinux: Dosing and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">
          "Management of heparin-induced thrombocytopenia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2049334131">
         <span class="h1">
          THROMBOLYTIC THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thrombolytic drugs are intravenously (IV) infused plasminogen activators that facilitate clot breakdown by converting plasminogen to plasmin, with subsequent cleavage of fibrin, fibrinogen, and factors V and VIII  (
         <a class="graphic graphic_figure graphicRef81428" href="/z/d/graphic/81428.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid39">
          39,45
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – Thrombolytic therapy is rarely used in the management of neonatal thrombosis. Use of this treatment modality is limited to situations wherein thrombus occludes a major vessel causing critical compromise of organs or limbs [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because of the high risk of major bleeding, decisions about thrombolytic therapy in newborns should ideally be made by a multidisciplinary team with input from surgical and hematology specialists. Parents/caregivers should be involved in the decision-making process and should be fully informed about the therapeutic options and risks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The alternative to thrombolytic therapy is surgical thrombectomy. However, this is rarely performed in neonates since the success of the procedure is limited by the small size of blood vessels and the clinical instability of newborns with thrombosis [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications
         </strong>
         – Contraindications to thrombolytic therapy are related to increased risk of bleeding and include [
         <a href="#rid48">
          48
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Major surgery or hemorrhage within the previous 10 days
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neurosurgery within three weeks
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe asphyxial event within seven days
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Any invasive procedure within three days
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Seizures within 48 hours
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prematurity &lt;32 weeks gestation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Septicemia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Active bleeding
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Inability to maintain platelets &gt;100,000/microL or fibrinogen &gt;100 mg/dL (&gt;1 g/L)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreatment evaluation and management
         </strong>
         – Pretreatment testing is the same as describe above (see
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above). In addition, we obtain D-dimer level before starting therapy. Thrombocytopenia (platelet count &lt;100,000/microL), low fibrinogen concentration (&lt;100 mg/dL [&lt;1g/L]), and severe coagulopathy should be corrected before initiating treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Fresh frozen plasma (FFP; 10 mL/kg) is given to all neonates prior to initiating thrombolytic therapy. This is because newborns have lower levels of plasminogen compared with older children and adults, which results in less plasmin generation and less clot lysis during thrombolytic therapy [
         <a href="#rid49">
          49,50
         </a>
         ]. Thus, administering FFP (which contains plasminogen) supplies this physiologic deficiency and helps promote fibrinolysis [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of agent
         </strong>
         – Recombinant tissue-type plasminogen activator (tPA) is the thrombolytic agent of choice. Streptokinase and urokinase have been used in newborns. However, compared with the other agents, tPA has better clot lysis in vitro [
         <a href="#rid49">
          49
         </a>
         ] and a lower risk of hypersensitivity [
         <a href="#rid51">
          51
         </a>
         ]. Urokinase is not labeled for this indication in the United States, nor is it approved for use in children.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration
         </strong>
         – The dose of tPA in newborns is extrapolated from studies involving older children and adults. tPA is administered as a continuous IV infusion (without a loading dose) via central or peripheral venous catheter. Reported dosing regimens of tPA for systemic therapy range from &lt;0.1 to 0.6 mg/kg per hour [
         <a href="#rid1">
          1
         </a>
         ]. In our practice, we typically start with a dose of 0.1 to 0.2 mg/kg per hour (without a loading dose) given over six hours  (
         <a class="graphic graphic_algorithm graphicRef134268" href="/z/d/graphic/134268.html" rel="external">
          algorithm 2
         </a>
         ). An infusion of
         <a class="drug drug_pediatric" data-topicid="13349" href="/z/d/drug information/13349.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) is concurrently administered at 10 units/kg per hour.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the response to the initial infusion is inadequate, it can be repeated with an increased dose. An alternative regimen consists of a 24-hour infusion at an initial dose of 0.03 mg/kg per hour, with subsequent dose adjustment according to response.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – Fibrinogen levels should be measured before and two hours after initiating therapy. The fibrinogen level should be maintained at &gt;100 mg/dL (&gt;1 g/L) by administering FFP and/or cryoprecipitate [
         <a href="#rid1">
          1
         </a>
         ]. The platelet count should be maintained at &gt;50,000/microL. (See
         <a class="medical medical_review" href="/z/d/html/7920.html" rel="external">
          "Clinical use of plasma components", section on 'Plasma products'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7943.html" rel="external">
          "Cryoprecipitate and fibrinogen concentrate"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We assess the response to therapy by monitoring for resolution of the thrombus on serial imaging. Other laboratory-based tests are generally not helpful in monitoring the therapeutic effect of the drug. Measuring the activated partial thromboplastin time (aPTT) is not informative, particularly if fibrinogen levels are low, fibrin degradation products are present, or the patient is concurrently receiving heparin therapy. The presence of D-dimers or fibrin degradation products indicates a fibrinolytic state; however, these tests do not provide a quantitative assessment of the drug's therapeutic effect. Nevertheless, monitoring the trend in the D-dimer level helps to qualitatively assess fibrinolytic effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Use of tPA for thrombolytic therapy in neonates is described in case reports and case series using a variety of doses and treatment regimens [
         <a href="#rid52">
          52-59
         </a>
         ]. In a review of 30 case reports and case series (94 patients), complete dissolution of the clot was reported in 70 percent of cases and partial lysis occurred in 23 percent [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse events
         </strong>
         – In the available reports, the frequencies of adverse events associated with tPA were as follows [
         <a href="#rid52">
          52,59
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No reported complications (40 percent of case reports)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Local nonsevere bleeding (25 to 35 percent)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe bleeding, including intraventricular hemorrhage (20 to 30 percent)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Death due to hemorrhage (one case report)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rethrombosis (7 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is difficult to know to what extent the bleeding complications in these studies were attributable to tPA since critically ill neonates are at risk for hemorrhage in the absence of thrombolytic therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of bleeding
         </strong>
         – Treatment of bleeding during tPA infusion involves the following steps:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stop the tPA and heparin infusions
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Administer cryoprecipitate
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Transfuse platelets, if needed
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The half-life for tPA is very short, and bleeding usually responds to these measures.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H34011514">
         <span class="h1">
          SPECIAL CIRCUMSTANCES
         </span>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Neonatal purpura fulminans
         </span>
         <span class="headingEndMark">
          —
         </span>
         Purpura fulminans in newborns is a rare life-threatening condition characterized by disseminated intravascular coagulation and hemorrhagic skin necrosis. (See
         <a class="medical medical_review" href="/z/d/html/5912.html" rel="external">
          "Neonatal thrombosis: Clinical features and diagnosis", section on 'Purpura fulminans'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial management
         </strong>
         – Neonatal purpura fulminans is initially treated with a source of exogenous protein C; heparin and antiplatelet agents are ineffective [
         <a href="#rid60">
          60-66
         </a>
         ]. Initial empiric treatment is often started before results of protein C and S levels are available. In this setting, administration of fresh frozen plasma (FFP; given at a dose of 10 to 20 mL/kg every 12 hours) is the appropriate intervention. Once protein C and S levels are resulted, subsequent therapy is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Protein C deficiency
         </strong>
         – For infants with protein C deficiency, either FFP or
         <a class="drug drug_pediatric" data-topicid="16776" href="/z/d/drug information/16776.html" rel="external">
          protein C concentrate
         </a>
         has been used with success:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         FFP is given at a dose of 10 to 20 mL/kg every 12 hours [
         <a href="#rid1">
          1,67
         </a>
         ]. Frequent dosing is necessary because the half-life of protein C in the circulation is only approximately 6 to 16 hours. However, administration of FFP on a frequent basis is limited by the development of hyperproteinemia, hypertension, loss of venous access, and potential for exposure to infectious viral agents [
         <a href="#rid68">
          68,69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A highly purified concentrate of protein C (Ceprotin [
         <a href="#rid70">
          70
         </a>
         ]) is given at a starting dose of 100 units/kg intravenously (IV), followed by 50 units/kg IV every six hours [
         <a href="#rid71">
          71-73
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="16776" href="/z/d/drug information/16776.html" rel="external">
          Protein C concentrate
         </a>
         is available in the United States and Canada for compassionate use in this condition.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Subsequent dosing of FFP or
         <a class="drug drug_pediatric" data-topicid="16776" href="/z/d/drug information/16776.html" rel="external">
          protein C concentrate
         </a>
         depends upon the patient's response because the half-life of protein C may be shortened considerably during acute thrombosis. The dose is titrated to achieve a trough level of protein C activity of 50 international units/dL [
         <a href="#rid73">
          73
         </a>
         ]. Treatment is continued until the lesions resolve (typically within six to eight weeks), and the infant is transitioned onto other anticoagulants. Protein C concentrate should not be confused with recombinant activated protein C (drotrecogin alfa), which is associated with bleeding complications in young infants and is no longer available.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Protein S deficiency
         </strong>
         – For infants with protein S deficiency, FFP is used. The initial dose is 10 to 20 mL/kg every 12 hours (the same dose that is used for protein C deficiency). The half-life of protein S is approximately 36 hours (plasma levels of protein S are 23 percent at two hours and 14 percent at 24 hours after an infusion of FFP 10 mL/kg) [
         <a href="#rid74">
          74,75
         </a>
         ]. The FFP dose titrated to a trough level of free protein S level of 30 international units/dL should be more than adequate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term management
         </strong>
         – Infants with purpura fulminans must be treated indefinitely to prevent thrombosis [
         <a href="#rid62">
          62,76-79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Options for long-term management include systemic anticoagulation (eg, with low molecular weight heparin [LMWH],
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          warfarin
         </a>
         , or a direct oral anticoagulant [DOAC]) and/or protein C supplementation (given subcutaneously) [
         <a href="#rid1">
          1
         </a>
         ]. If LMWH is used, the target anti-factor Xa concentration is 0.5 to 1 units/mL. If warfarin is used, the international normalized ratio (INR) usually should be maintained between 2.5 to 3.5. A lower INR of 1.5 to 2.5 is appropriate if the patient is also treated with
         <a class="drug drug_pediatric" data-topicid="16776" href="/z/d/drug information/16776.html" rel="external">
          protein C concentrate
         </a>
         ; a higher INR of 3 to 4.5 is appropriate if the patient has warfarin-induced skin necrosis [
         <a href="#rid80">
          80
         </a>
         ]. Because LMWH has a more predictable and stable anticoagulation response in young patients, we generally prefer it over warfarin. We also prefer LMWH over DOACs because there is more experience using LMWH in infants and young children. (See
         <a class="local">
          'Choice of agent'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Subcutaneous administration of
         <a class="drug drug_pediatric" data-topicid="16776" href="/z/d/drug information/16776.html" rel="external">
          protein C concentrate
         </a>
         has been described in several case reports [
         <a href="#rid81">
          81-85
         </a>
         ]. Optimal dosing is not established. Subcutaneous administration avoids the potential hazards of long-term central venous access.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Liver transplantation can correct homozygous protein C deficiency and has been used for a patient for whom protein C replacement therapy was not available [
         <a href="#rid86">
          86
         </a>
         ]. A combined liver and renal transplant was successfully used for a patient who developed renal failure due to renal vein thrombosis (RVT) [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2186171970">
         <span class="h2">
          Congenital nephrotic syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants with congenital nephrotic syndrome are at increased risk for developing venous thromboembolism (VTE). For infants with nephrotic syndrome who develop VTE, we suggest continuing anticoagulant therapy beyond the usual three-month course, at either therapeutic or prophylactic doses, as long as the nephrotic syndrome persists [
         <a href="#rid1">
          1
         </a>
         ]. For infants who have not experienced VTE, the role of anticoagulant therapy for primary prophylaxis has not been established [
         <a href="#rid88">
          88
         </a>
         ]. Decisions about the treatment of such patients typically depend on the severity of the nephrotic syndrome and presence of other risk factors. As an example, the authors of this topic review would initiate primary prophylaxis for an infant with severe nephrotic syndrome and one or more other risk factors (eg, an inherited thrombophilia or central venous catheter [CVC]). Patients with congenital nephrotic syndrome tend to have a low antithrombin (AT) level, and, thus, the dose of LMWH required to achieve an adequate anti-Xa level is substantially higher than is typically used (eg,
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         3 mg/kg per dose). In patients with renal insufficiency, the dose of LMWH should be adjusted. (See
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22502859">
         <span class="h1">
          PREVENTION OF CATHETER-ASSOCIATED THROMBOSIS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arterial catheters
         </strong>
         – It is standard practice in most neonatal intensive care units (NICUs) to use a low-dose heparin infusion to maintain patency of arterial catheters, including both umbilical artery catheters and peripheral arterial catheters. This typically consists of an infusion of normal
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         fluid containing
         <a class="drug drug_pediatric" data-topicid="13349" href="/z/d/drug information/13349.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) at a concentration of 0.25 to 1.0 units/mL at a rate of 0.5 to 1 mL per hour [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This practice is supported by clinical trials and observational data [
         <a href="#rid89">
          89-91
         </a>
         ]. In a meta-analysis of five trials, low-dose heparin decreased the risk of umbilical artery catheter occlusion (relative risk 0.20, 95% CI 0.11-0.35) [
         <a href="#rid89">
          89
         </a>
         ]. The risk of other serious complications (aortic thrombosis, intraventricular hemorrhage, death, or clinical ischemic events) did not appear to be affected, although there were too few events to draw firm conclusions. Data supporting the use of heparin for maintenance of peripheral arterial catheters in neonates are more limited [
         <a href="#rid90">
          90,91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central venous catheters (CVCs)
         </strong>
         – Heparin flushes (either as a continuous low-dose infusion or intermittent flushes) are commonly used in the NICU setting to maintain patency of umbilical venous catheters (UVCs) and peripherally inserted central catheters. In a meta-analysis of three small clinical trials (n = 267), a continuous heparin infusion reduced the risk of catheter occlusion (relative risk 0.28, 95% CI 0.15-0.53) but did not reduce rates of thrombosis or catheter-related sepsis [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Obstructed CVCs can be cleared with local instillation of tissue-type plasminogen activator (tPA; 0.25 to 0.50 mg) [
         <a href="#rid48">
          48
         </a>
         ]. It is important to limit the volume infused to the dead space of the catheter to avoid systemic administration of tPA. (See
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Blocked central venous catheter'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H377709861">
         <span class="h1">
          OUTCOME
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reported mortality rate associated with neonatal thrombosis ranges from 10 to 30 percent, depending upon the population studied [
         <a href="#rid93">
          93,94
         </a>
         ]. The mortality rates in these reports are difficult to interpret as most neonates in these studies had underlying critical illness, which likely contributed to the poor outcome.
        </p>
        <p>
         Long-term complications associated with neonatal thrombosis depend on the location and type of thrombus:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Catheter-associated thrombosis
         </strong>
         – Most infants with asymptomatic catheter-associated thrombus do not develop long-term sequelae. For infants with occlusive deep vein thrombosis (DVT), there is potential risk of developing post-thrombotic syndrome (PTS), a disorder characterized by edema and impaired viability of subcutaneous tissue in an extremity. The condition is caused by incompetent perforating valves, resulting in blood flow directed from deep to peripheral veins. PTS is increasingly recognized in older infants and children, but it is less common following neonatal thrombosis. In one series of 95 neonates with catheter-related iliofemoral DVT who were followed for a median of four years, approximately 40 percent developed evidence of mild PTS; however clinically relevant PTS (ie, greater than mild) occurred in only 1 percent of patients [
         <a href="#rid95">
          95
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Post-thrombotic syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Severe arterial thrombosis in an extremity can result in long-term arterial insufficiency. This may impair growth of the affected limb [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Portal vein thrombosis (PVT)
         </strong>
         – Long-term complications of PVT are uncommon but may include hepatic lobar atrophy and/or portal hypertension [
         <a href="#rid10">
          10,97,98
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5912.html" rel="external">
          "Neonatal thrombosis: Clinical features and diagnosis", section on 'Portal vein thrombosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Renal vein thrombosis (RVT)
         </strong>
         – Neonatal RVT can be associated with considerable morbidity, including chronic kidney disease and systemic hypertension [
         <a href="#rid9">
          9,99-101
         </a>
         ]. In a systematic review of 13 case series that included 271 patients with neonatal RVT, there were nine reported deaths, all of which were related to comorbid conditions (eg, respiratory failure, multiorgan failure, sepsis) [
         <a href="#rid6">
          6
         </a>
         ]. In the studies that reported long-term outcome, 20 percent of surviving patients developed hypertension and 71 percent had chronic kidney disease, including eight patients who required chronic renal replacement therapy (eg, dialysis and transplantation).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H339822577">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117261.html" rel="external">
          "Society guideline links: Thrombotic diseases in infants and children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27600983">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Removal of indwelling catheters
         </strong>
         – Most thrombotic events in neonates are catheter associated. Thus, management should generally include removal of the catheter, if possible. (See
         <a class="local">
          'Catheter-associated thrombosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rationale for anticoagulant therapy
         </strong>
         – Because prothrombotic risk factors in neonates usually are transient (eg, indwelling catheter, critical illness), the recurrence risk is low. Therefore, the primary goals of treatment are to prevent thrombus extension and minimize end-organ damage. (See
         <a class="local">
          'General approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection
         </strong>
         – When choosing between conservative management (ie, supportive care and close monitoring) versus initiating anticoagulation, we suggest the following approach based upon the location of the thrombus:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Renal vein thrombosis (RVT)
         </strong>
         – For most neonates with RVT, we suggest anticoagulation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, conservative management is reasonable if the RVT is unilateral without extension into inferior vena cava (IVC) and renal function is normal. Infants with bilateral RVT or extension into the IVC are more likely to benefit from anticoagulation; thrombolytic therapy can also be considered in such neonates. (See
         <a class="local">
          'Renal vein thrombosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Portal vein thrombosis (PVT)
         </strong>
         – For most neonates with PVT that is limited to the left portal vein, we suggest conservative management (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). If the thrombus extends into the main portal vein, we suggest anticoagulation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Portal vein thrombosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Right atrial (RA) thrombosis
         </strong>
         – For most neonates with RA thrombosis, we suggest anticoagulation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Conservative management is a reasonable alternative if the neonate is asymptomatic and the thrombus has low-risk features (as described above). If the thrombus is compromising cardiac function, thrombolytic therapy can be considered. (See
         <a class="local">
          'Right atrial thrombosis'
         </a>
         above and
         <a class="local">
          'Thrombolytic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Catheter-associated venous thrombosis in other locations
         </strong>
         – For most neonates with catheter-associated venous thrombosis in locations other than the RV, PV, or RA who are asymptomatic, we suggest conservative management initially (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For neonates with symptomatic catheter-associated thrombosis and those with asymptomatic thrombosis that extends during conservative management, we suggest anticoagulation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Catheter-associated thrombosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Arterial thrombosis
         </strong>
         – For neonates with arterial thrombosis causing clinically significant impairment of blood flow to an extremity or vital organ, we recommend anticoagulation (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). Any associated arterial catheter should be removed. Thrombolytic therapy may be warranted if the thrombosis is life-threatening or if the viability of a limb or organ is jeopardized. A surgical consultation should be obtained in such cases. (See
         <a class="local">
          'Arterial thrombosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Central nervous system
         </strong>
         – Management of neonatal stroke is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/114253.html" rel="external">
          "Stroke in the newborn: Management and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreatment evaluation
         </strong>
         – Before starting anticoagulant therapy, pretreatment testing includes (see
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Baseline coagulation tests
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complete blood count with platelet count
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Kidney and liver function tests
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cranial ultrasound
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of anticoagulant
         </strong>
         – For most neonates requiring anticoagulation therapy, we suggest low molecular weight heparin (LMWH) rather than other agents (eg,
         <a class="drug drug_pediatric" data-topicid="13349" href="/z/d/drug information/13349.html" rel="external">
          unfractionated heparin
         </a>
         [UFH], direct oral anticoagulants [DOACs]) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Compared with UFH, LMWH has a more predicable response in neonates, requires less laboratory monitoring and dose adjustment, and is administered subcutaneously (and therefore does not require a dedicated intravenous [IV] catheter). LMWH is preferred over DOACs because there are few data on DOACs in the neonatal population. (See
         <a class="local">
          'Choice of agent'
         </a>
         above and
         <a class="local">
          'Low molecular weight heparin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         UFH may be preferred for initial therapy in some circumstances, such as in patients with renal failure or those with bleeding risks who require finely tuned titration and the ability to quickly turn on or off the infusion. (See
         <a class="local">
          'Unfractionated heparin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing, monitoring, and adjustment
         </strong>
         – Pediatric dosing for different LMWH agents is summarized in the table  (
         <a class="graphic graphic_table graphicRef64075" href="/z/d/graphic/64075.html" rel="external">
          table 1
         </a>
         ). Dose adjustment is necessary for patients with kidney impairment. (See
         <a class="local">
          'Dose'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The LMWH dose is adjusted according to the anti-factor Xa level measured four to six hours after the dose. For patients receiving therapeutic anticoagulation, the target range for anti-factor Xa levels is 0.5 to 1 units/mL. (See
         <a class="local">
          'Monitoring and dose adjustment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If UFH is selected, the initial dose is 28 units/kg per hour IV. The approach to adjusting the infusion based upon anti-factor Xa level and aPTT is summarized in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef134270" href="/z/d/graphic/134270.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Unfractionated heparin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of therapy
         </strong>
         – The usual duration of anticoagulant therapy is six weeks to three months. Our approach is to monitor the thrombus with ultrasound and continue therapy until the thrombus has resolved and the patient is asymptomatic or for three months, whichever is shorter. If the thrombus was related to a central venous catheter (CVC), the CVC should be removed before stopping therapy. (See
         <a class="local">
          'Treatment based on thrombus location'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limited role of thrombolytic therapy
         </strong>
         – Thrombolytic therapy is rarely required in the management of neonatal thrombosis; its use is limited to patients in whom major vessel occlusion is causing critical compromise of organs or limbs. Decisions about thrombolytic therapy in newborns should ideally be made by a multidisciplinary team including input from surgical and hematology specialists. When thrombolytic therapy is used, we suggest recombinant tissue-type plasminogen activator (tPA) rather than other agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The approach is summarized in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef134268" href="/z/d/graphic/134268.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Thrombolytic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of catheter-associated thrombosis
         </strong>
         – For neonates with indwelling arterial or central venous catheters, we suggest low-dose UFH (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ) to prevent thrombosis and maintain catheter patency. For arterial catheters, UFH is given as a low-dose continuous infusion (0.25 to 1.0 units/mL in normal
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         at a rate of 0.5 to 1 mL per hour); for CVCs, UFH can be given either as a continuous low-dose infusion or intermittent flushes. The available clinical trial data suggest that low-dose heparin reduces the risk of catheter occlusion, though it is uncertain whether this practice reduces catheter-associated thrombotic complications. (See
         <a class="local">
          'Prevention of catheter-associated thrombosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcome
         </strong>
         – Long-term complications associated with neonatal thrombosis depend on the location and type of thrombus. Most infants with asymptomatic catheter-associated thrombus have no long-term sequelae, though there is potential risk of developing post-thrombotic syndrome (PTS). Long-term complications of PVT are uncommon but may include hepatic lobar atrophy and/or portal hypertension. RVT can be associated with considerable morbidity, particularly chronic kidney disease and hypertension. (See
         <a class="local">
          'Outcome'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2018; 2:3292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrew M. Society for Pediatric Research Presidential Address 1998: the SPR and 1-800-NO-CLOTS: a common vision. Pediatr Res 1998; 44:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones S, Monagle P, Newall F. Do asymptomatic clots in children matter? Thromb Res 2020; 189:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenberg NA, Kittelson JM, Abshire TC, et al. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA 2022; 327:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau KK, Stoffman JM, Williams S, et al. Neonatal renal vein thrombosis: review of the English-language literature between 1992 and 2006. Pediatrics 2007; 120:e1278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messinger Y, Sheaffer JW, Mrozek J, et al. Renal outcome of neonatal renal venous thrombosis: review of 28 patients and effectiveness of fibrinolytics and heparin in 10 patients. Pediatrics 2006; 118:e1478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuckuviene R, Christensen AL, Helgestad J, et al. Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study. J Pediatr 2011; 159:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouellette AC, Darling EK, Sivapathasundaram B, et al. Incidence, Risk Factors, and Outcomes of Neonatal Renal Vein Thrombosis in Ontario: Population-Based Cohort Study. Kidney360 2020; 1:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams S, Chan AK. Neonatal portal vein thrombosis: diagnosis and management. Semin Fetal Neonatal Med 2011; 16:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang JY, Williams S, Brandão LR, Chan AK. Neonatal and childhood right atrial thrombosis: recognition and a risk-stratified treatment approach. Blood Coagul Fibrinolysis 2010; 21:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang JY, Williams S, Brandão LR, et al. Neonatal and childhood right atrial thrombosis: critical clot size. Blood Coagul Fibrinolysis 2013; 24:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albisetti M, Andrew M. Low molecular weight heparin in children. Eur J Pediatr 2002; 161:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Heijden JF, Prins MH, Büller HR. For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? Thromb Res 2000; 100:V121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massicotte P, Adams M, Marzinotto V, et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996; 128:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000; 136:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malowany JI, Monagle P, Knoppert DC, et al. Enoxaparin for neonatal thrombosis: a call for a higher dose for neonates. Thromb Res 2008; 122:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klaassen ILM, Sol JJ, Suijker MH, et al. Are low-molecular-weight heparins safe and effective in children? A systematic review. Blood Rev 2019; 33:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauman ME, Black KL, Bauman ML, et al. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing. Thromb Res 2009; 123:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chander A, Nagel K, Wiernikowski J, et al. Evaluation of the use of low-molecular-weight heparin in neonates: a retrospective, single-center study. Clin Appl Thromb Hemost 2013; 19:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Streif W, Goebel G, Chan AK, Massicotte MP. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed 2003; 88:F365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatt MD, Paes BA, Chan AK. How to use unfractionated heparin to treat neonatal thrombosis in clinical practice. Blood Coagul Fibrinolysis 2016; 27:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ting J, Yeung K, Paes B, et al. How to use low-molecular-weight heparin to treat neonatal thrombosis in clinical practice. Blood Coagul Fibrinolysis 2021; 32:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002; 116:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanslik A, Kitzmüller E, Thom K, et al. Incidence of thrombotic and bleeding complications during cardiac catheterization in children: comparison of high-dose vs. low-dose heparin protocols. J Thromb Haemost 2011; 9:2353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994; 35:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995; 74:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt B, Buchanan MR, Ofosu F, et al. Antithrombotic properties of heparin in a neonatal piglet model of thrombin-induced thrombosis. Thromb Haemost 1988; 60:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz R, Moffett BS, Karabinas S, et al. Antithrombin Concentrate Use in Children Receiving Unfractionated Heparin for Acute Thrombosis. J Pediatr 2015; 167:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Reilly MS. Antiangiogenic antithrombin. Semin Thromb Hemost 2007; 33:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt B, Gillie P, Mitchell L, et al. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998; 158:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newall F, Johnston L, Ignjatovic V, Monagle P. Unfractionated heparin therapy in infants and children. Pediatrics 2009; 123:e510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schechter T, Finkelstein Y, Ali M, et al. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels. J Thromb Haemost 2012; 10:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spadone D, Clark F, James E, et al. Heparin-induced thrombocytopenia in the newborn. J Vasc Surg 1992; 15:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranze O, Ranze P, Magnani HN, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 1999; 158 Suppl 3:S130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Risch L, Huber AR, Schmugge M. Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. Thromb Res 2006; 118:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrew ME, Monagle P, deVeber G, Chan AK. Thromboembolic disease and antithrombotic therapy in newborns. Hematology Am Soc Hematol Educ Program 2001; :358.
          </a>
         </li>
         <li class="breakAll">
          Bayer Inc. Xarelto (rivaroxaban tablets) Product Monograph. 2021. Available at: https://pdf.hres.ca/dpd_pm/00059600.PDF (Accessed on July 14, 2021).
         </li>
         <li class="breakAll">
          European Medicines Agency. Xarelto Assessment Report. 2020. Available at: https://www.ema.europa.eu/en/documents/variation-report/xarelto-h-c-944-x-0074-g-epar-assessment-report-variation_en.pdf (Accessed on December 11, 2020).
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA Approves First Oral Blood Thinning Medication for Children. 2021. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-blood-thinning-medication-children (Accessed on June 25, 2021).
         </li>
         <li class="breakAll">
          Canadian Pediatric Thrombosis &amp; Hemostasis Network https://cpthn.ca/wp-content/uploads/2023/01/CPTHN-Rivaroxaban-Guidance-Document_Final-Sep-2021-002.pdf (Accessed on August 16, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young G, Boshkov LK, Sullivan JE, et al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer 2011; 56:1103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edstrom CS, Christensen RD. Evaluation and treatment of thrombosis in the neonatal intensive care unit. Clin Perinatol 2000; 27:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin PH, Dodson TF, Bush RL, et al. Surgical intervention for complications caused by femoral artery catheterization in pediatric patients. J Vasc Surg 2001; 34:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hedrick M, Elkins RC, Knott-Craig CJ, Razook JD. Successful thrombectomy for thrombosis of the right side of the heart after the Fontan operation. Report of two cases and review of the literature. J Thorac Cardiovasc Surg 1993; 105:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manco-Johnson MJ, Grabowski EF, Hellgreen M, et al. Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002; 88:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrew M, Brooker L, Leaker M, et al. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thromb Haemost 1992; 68:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ries M, Easton RL, Longstaff C, et al. Differences between neonates and adults in tissue-type-plasminogen activator (t-PA)-catalyzed plasminogen activation with various effectors and in carbohydrate sequences of fibrinogen chains. Thromb Res 2001; 103:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephens MB, Pepper PV. Streptokinase therapy. Recognizing and treating allergic reactions. Postgrad Med 1998; 103:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartmann J, Hussein A, Trowitzsch E, et al. Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature. Arch Dis Child Fetal Neonatal Ed 2001; 85:F18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farnoux C, Camard O, Pinquier D, et al. Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates. J Pediatr 1998; 133:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrari F, Vagnarelli F, Gargano G, et al. Early intracardiac thrombosis in preterm infants and thrombolysis with recombinant tissue type plasminogen activator. Arch Dis Child Fetal Neonatal Ed 2001; 85:F66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta AA, Leaker M, Andrew M, et al. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr 2001; 139:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nowak-Göttl U, Auberger K, Halimeh S, et al. Thrombolysis in newborns and infants. Thromb Haemost 1999; 82 Suppl 1:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leaker M, Massicotte MP, Brooker LA, Andrew M. Thrombolytic therapy in pediatric patients: a comprehensive review of the literature. Thromb Haemost 1996; 76:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Segaier M, Khan MA, Khan ZU, et al. Recombinant Tissue Plasminogen Activator in the Treatment of Neonates with Intracardiac and Great Vessels Thrombosis. Pediatr Cardiol 2015; 36:1582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grizante-Lopes P, Garanito MP, Celeste DM, et al. Thrombolytic therapy in preterm infants: Fifteen-year experience. Pediatr Blood Cancer 2020; 67:e28544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Branson HE, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet 1983; 2:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marciniak E, Wilson HD, Marlar RA. Neonatal purpura fulminans: a genetic disorder related to the absence of protein C in blood. Blood 1985; 65:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuen P, Cheung A, Lin HJ, et al. Purpura fulminans in a Chinese boy with congenital protein C deficiency. Pediatrics 1986; 77:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Estellés A, Garcia-Plaza I, Dasí A, et al. Severe inherited "homozygous" protein C deficiency in a newborn infant. Thromb Haemost 1984; 52:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sills RH, Marlar RA, Montgomery RR, et al. Severe homozygous protein C deficiency. J Pediatr 1984; 105:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rappaport ES, Speights VO, Helbert B, et al. Protein C deficiency. South Med J 1987; 80:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fruchtman Y, Strauss T, Rubinstein M, et al. Skin Necrosis and Purpura Fulminans in Children With and Without Thrombophilia--A Tertiary Center's Experience. Pediatr Hematol Oncol 2015; 32:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990; 16:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vigano D'Angelo S, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986; 77:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viganò S, Mannucci PM, Solinas S, et al. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol 1984; 57:213.
          </a>
         </li>
         <li class="breakAll">
          DailyMed. Ceprotin- protein c concentrate human kit. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=926914a9-78b2-40ea-b37d-2a55c09bf275 (Accessed on November 17, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dreyfus M, Magny JF, Bridey F, et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991; 325:1565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conard J, Bauer KA, Gruber A, et al. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood 1993; 82:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price VE, Ledingham DL, Krümpel A, Chan AK. Diagnosis and management of neonatal purpura fulminans. Semin Fetal Neonatal Med 2011; 16:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahasandana C, Suvatte V, Marlar RA, et al. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet 1990; 335:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahasandana C, Suvatte V, Chuansumrit A, et al. Homozygous protein S deficiency in an infant with purpura fulminans. J Pediatr 1990; 117:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters C, Casella JF, Marlar RA, et al. Homozygous protein C deficiency: observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy. Pediatrics 1988; 81:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Plaza I, Jimenez-Astorga C, Borrego D, Marty ML. Coumarin prophylaxis for fulminant purpura syndrome due to homozygous protein C deficiency. Lancet 1985; 1:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartman KR, Manco-Johnson M, Rawlings JS, et al. Homozygous protein C deficiency: early treatment with warfarin. Am J Pediatr Hematol Oncol 1989; 11:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monagle P, Andrew M, Halton J, et al. Homozygous protein C deficiency: description of a new mutation and successful treatment with low molecular weight heparin. Thromb Haemost 1998; 79:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minford AM, Parapia LA, Stainforth C, Lee D. Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate. Br J Haematol 1996; 93:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanz-Rodriguez C, Gil-Fernández JJ, Zapater P, et al. Long-term management of homozygous protein C deficiency: replacement therapy with subcutaneous purified protein C concentrate. Thromb Haemost 1999; 81:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Kort EH, Vrancken SL, van Heijst AF, et al. Long-term subcutaneous protein C replacement in neonatal severe protein C deficiency. Pediatrics 2011; 127:e1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathias M, Khair K, Burgess C, Liesner R. Subcutaneous administration of protein C concentrate. Pediatr Hematol Oncol 2004; 21:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piccini B, Capirchio L, Lenzi L, et al. Continuous subcutaneous infusion of protein C concentrate using an insulin pump in a newborn with congenital protein C deficiency. Blood Coagul Fibrinolysis 2014; 25:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee MJ, Kim KM, Kim JS, et al. Long-term survival of a child with homozygous protein C deficiency successfully treated with living donor liver transplantation. Pediatr Transplant 2009; 13:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angelis M, Pegelow CH, Khan FA, et al. En bloc heterotopic auxiliary liver and bilateral renal transplant in a patient with homozygous protein C deficiency. J Pediatr 2001; 138:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau KK, Chan HH, Massicotte P, Chan AK. Thrombotic complications of neonates and children with congenital nephrotic syndrome. Curr Pediatr Rev 2014; 10:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrington KJ. Umbilical artery catheters in the newborn: effects of heparin. Cochrane Database Syst Rev 2000; :CD000507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Randolph AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomised controlled trials. BMJ 1998; 316:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzi M, Goldenberg N, Bonduel M, et al. Catheter-Related Arterial Thrombosis in Neonates and Children: A Systematic Review. Thromb Haemost 2018; 118:1058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah PS, Shah VS. Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters. Cochrane Database Syst Rev 2008; :CD002772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nowak-Göttl U, von Kries R, Göbel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997; 76:F163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995; 96:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avila ML, Pullenayegum E, Williams S, et al. Post-thrombotic syndrome and other outcomes of lower extremity deep vein thrombosis in children. Blood 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macnicol MF, Anagnostopoulos J. Arrest of the growth plate after arterial cannulation in infancy. J Bone Joint Surg Br 2000; 82:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kooiman AM, Kootstra G, Zwierstra RP. Portal hypertension in children due to thrombosis of the portal vein. Neth J Surg 1982; 34:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Junker P, Egeblad M, Nielsen O, Kamper J. Umbilical vein catheterization and portal hypertension. Acta Paediatr Scand 1976; 65:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zigman A, Yazbeck S, Emil S, Nguyen L. Renal vein thrombosis: a 10-year review. J Pediatr Surg 2000; 35:1540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marks SD, Massicotte MP, Steele BT, et al. Neonatal renal venous thrombosis: clinical outcomes and prevalence of prothrombotic disorders. J Pediatr 2005; 146:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winyard PJ, Bharucha T, De Bruyn R, et al. Perinatal renal venous thrombosis: presenting renal length predicts outcome. Arch Dis Child Fetal Neonatal Ed 2006; 91:F273.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5911 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315277" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30482766" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9853936" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Society for Pediatric Research Presidential Address 1998: the SPR and 1-800-NO-CLOTS: a common vision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32145462" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Do asymptomatic clots in children matter?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35015038" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17974721" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Neonatal renal vein thrombosis: review of the English-language literature between 1992 and 2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17000780" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Renal outcome of neonatal renal venous thrombosis: review of 28 patients and effectiveness of fibrinolytics and heparin in 10 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21596390" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35372933" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Incidence, Risk Factors, and Outcomes of Neonatal Renal Vein Thrombosis in Ontario: Population-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21925985" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Neonatal portal vein thrombosis: diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20305543" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Neonatal and childhood right atrial thrombosis: recognition and a risk-stratified treatment approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23632382" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Neonatal and childhood right atrial thrombosis: critical clot size.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9278467" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Low-molecular-weight heparins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11954754" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Low molecular weight heparin in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11053625" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8774496" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10753240" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The use of low molecular weight heparin in pediatric patients: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18207492" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Enoxaparin for neonatal thrombosis: a call for a higher dose for neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30041977" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Are low-molecular-weight heparins safe and effective in children? A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19038418" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23478571" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Evaluation of the use of low-molecular-weight heparin in neonates: a retrospective, single-center study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12937038" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1789820" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A standard heparin nomogram for the management of heparin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26656898" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : How to use unfractionated heparin to treat neonatal thrombosis in clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34102656" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : How to use low-molecular-weight heparin to treat neonatal thrombosis in clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11841415" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22008390" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Incidence of thrombotic and bleeding complications during cardiac catheterization in children: comparison of high-dose vs. low-dose heparin protocols.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8134203" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Heparin therapy in pediatric patients: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8578498" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Developmental hemostasis: relevance to thromboembolic complications in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3217922" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Antithrombotic properties of heparin in a neonatal piglet model of thrombin-induced thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26148660" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Antithrombin Concentrate Use in Children Receiving Unfractionated Heparin for Acute Thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18000792" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Antiangiogenic antithrombin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9700123" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19221154" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Unfractionated heparin therapy in infants and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22244010" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1735891" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Heparin-induced thrombocytopenia in the newborn.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10650852" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16709481" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11722993" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Thromboembolic disease and antithrombotic therapy in newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11722993" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Thromboembolic disease and antithrombotic therapy in newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11722993" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Thromboembolic disease and antithrombotic therapy in newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11722993" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Thromboembolic disease and antithrombotic therapy in newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11722993" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Thromboembolic disease and antithrombotic therapy in newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21488155" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10986632" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Evaluation and treatment of thrombosis in the neonatal intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11743563" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Surgical intervention for complications caused by femoral artery catheterization in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8429658" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Successful thrombectomy for thrombosis of the right side of the heart after the Fontan operation. Report of two cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12152658" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1440499" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11672579" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Differences between neonates and adults in tissue-type-plasminogen activator (t-PA)-catalyzed plasminogen activation with various effectors and in carbohydrate sequences of fibrinogen chains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9519032" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Streptokinase therapy. Recognizing and treating allergic reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11420316" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9672527" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11420328" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Early intracardiac thrombosis in preterm infants and thrombolysis with recombinant tissue type plasminogen activator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11713447" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10695499" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Thrombolysis in newborns and infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8865517" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Thrombolytic therapy in pediatric patients: a comprehensive review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25991571" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Recombinant Tissue Plasminogen Activator in the Treatment of Neonates with Intracardiac and Great Vessels Thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32710708" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Thrombolytic therapy in preterm infants: Fifteen-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6139528" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3838081" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Neonatal purpura fulminans: a genetic disorder related to the absence of protein C in blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3754634" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Purpura fulminans in a Chinese boy with congenital protein C deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6548587" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Severe inherited "homozygous" protein C deficiency in a newborn infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6547978" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Severe homozygous protein C deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3810223" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Protein C deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26436558" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Skin Necrosis and Purpura Fulminans in Children With and Without Thrombophilia--A Tertiary Center's Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2149204" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3511097" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6547348" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6547348" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1944440" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8353282" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21839696" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Diagnosis and management of neonatal purpura fulminans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1967377" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Neonatal purpura fulminans associated with homozygous protein S deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2231208" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Homozygous protein S deficiency in an infant with purpura fulminans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9746774" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3340476" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Homozygous protein C deficiency: observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2857966" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Coumarin prophylaxis for fulminant purpura syndrome due to homozygous protein C deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2618972" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Homozygous protein C deficiency: early treatment with warfarin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9569188" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Homozygous protein C deficiency: description of a new mutation and successful treatment with low molecular weight heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8611462" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10404762" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Long-term management of homozygous protein C deficiency: replacement therapy with subcutaneous purified protein C concentrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21482600" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Long-term subcutaneous protein C replacement in neonatal severe protein C deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15552819" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Subcutaneous administration of protein C concentrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24509341" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Continuous subcutaneous infusion of protein C concentrate using an insulin pump in a newborn with congenital protein C deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18482214" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Long-term survival of a child with homozygous protein C deficiency successfully treated with living donor liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11148525" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : En bloc heterotopic auxiliary liver and bilateral renal transplant in a patient with homozygous protein C deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25088336" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Thrombotic complications of neonates and children with congenital nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10796377" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Umbilical artery catheters in the newborn: effects of heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9550955" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29695022" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Catheter-Related Arterial Thrombosis in Neonates and Children: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18425882" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9175945" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Neonatal symptomatic thromboembolism in Germany: two year survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7478839" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Neonatal thrombosis: report of a prospective Canadian and international registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27474755" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Post-thrombotic syndrome and other outcomes of lower extremity deep vein thrombosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10755421" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Arrest of the growth plate after arterial cannulation in infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6981785" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Portal hypertension in children due to thrombosis of the portal vein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/937001" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Umbilical vein catheterization and portal hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11083418" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Renal vein thrombosis: a 10-year review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15973324" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Neonatal renal venous thrombosis: clinical outcomes and prevalence of prothrombotic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16464938" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Perinatal renal venous thrombosis: presenting renal length predicts outcome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
